TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25180584

Group type: EXPERIMENTAL
Intervention: High-quantity lipid-based nutrient supplements (HQ-LNS) with cash (€38/month)
Number of subjects: 5395

Group type: EXPERIMENTAL
Intervention: Medium-quantity lipid-based nutrient supplements (MQ-LNS) with cash (€38/month)
Number of subjects: 5395

Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+) with cash (€38/month)
Number of subjects: 5395

Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+) with family food ration
Number of subjects: 5395

Group type: EXPERIMENTAL
Intervention: High-quantity lipid-based nutrient supplements (HQ-LNS) only
Number of subjects: 5395

Group type: EXPERIMENTAL
Intervention: Super Cereal Plus (SC+) only
Number of subjects: 5395

Group type: COMPARATOR
Intervention: Cash transfer only (€43/month)
Number of subjects: 5395
Study: 25181387

Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy for ovarian cancer
Number of subjects: 1
Study: 25181608

Group type: EXPERIMENTAL
Intervention: Guided self-help weight loss program (12 brief sessions across 5 months)
Number of subjects: 50
Study: 25182067

Group type: EXPERIMENTAL
Intervention: Public health nurse-administered program in Prince Edward Island
Number of subjects: 2

Group type: COMPARATOR
Intervention: Physician-administered program in Nova Scotia
Number of subjects: 2
Study: 25183428

Group type: EXPERIMENTAL
Intervention: Residential proximity to a major road
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Distance-weighted traffic density within 100 meters
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Distance-weighted traffic density within 200 meters
Number of subjects: 183
Study: 25183991

Group type: EXPERIMENTAL
Intervention: 5En%-protein diet
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 15En%-protein diet
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 30En%-protein diet
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Soy-containing diets (15En% and 30En%)
Number of subjects: 70
Study: 25185097

Group type: EXPERIMENTAL
Intervention: TH-302 plus doxorubicin induction treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: TH-302 maintenance therapy
Number of subjects: 91
Study: 25185630

Group type: EXPERIMENTAL
Intervention: Nonsurgical management for fecal incontinence
Number of subjects: 0
Study: 25185712

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide at 120 mg/kg plus cyclosporine and prophylaxis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide at 120 mg/kg
Number of subjects: 22
Study: 25185778

Group type: COMPARATOR
Intervention: Routine diabetes care according to national guidelines (623 individuals)
Number of subjects: 1533

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial target-driven management (910 individuals)
Number of subjects: 1533
Study: 25185797

Group type: EXPERIMENTAL
Intervention: Recombinant Lactococcus lactis
Number of subjects: 0
Study: 25186534

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25186535

Group type: EXPERIMENTAL
Intervention: ADOA patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (mutation-free relatives)
Number of subjects: 43
Study: 25186780

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy with adjunctive systemic antibiotics
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 97
Study: 25187030

Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a (63μg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a (125μg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neopterin levels
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Number of subjects: 35
Study: 25187694

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib 0.3 mg
Number of subjects: 46
Study: 25187881

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25187919

Group type: EXPERIMENTAL
Intervention: LdT or LAM
Number of subjects: 700

Group type: COMPARATOR
Intervention: NTx
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: LdT
Number of subjects: 700
Study: 25190134

Group type: EXPERIMENTAL
Intervention: Presepsin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Presepsin (4th quartile levels)
Number of subjects: 116
Study: 25190203

Group type: EXPERIMENTAL
Intervention: Globus pallidus infarcts in patients with isolated methylmalonic acidemia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neuroanatomic scoring system based on infarct patterns
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prevalence of globus pallidus infarcts by methylmalonic acidemia class
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lacunar infarcts in the pars reticulata of the substantia nigra
Number of subjects: 40
Study: 25190591

Group type: COMPARATOR
Intervention: Higher ESS (≥1 Pa)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low ESS (<1 Pa)
Number of subjects: 21
Study: 25190605

Group type: EXPERIMENTAL
Intervention: Root canal therapy (RCT)
Number of subjects: 708
Study: 25190633

Group type: EXPERIMENTAL
Intervention: PROVIVO instrument (Patient-Reported Outcomes of long-term survivors after allogeneic SCT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE item bundle
Number of subjects: 15
Study: 25190651

Group type: EXPERIMENTAL
Intervention: Adaptive optics scanning light ophthalmoscopy (AOSLO)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Autofluorescence (AF)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Scanning light ophthalmoscopy (SLO)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of AOSLO and OCT
Number of subjects: 75
Study: 25190675

Group type: EXPERIMENTAL
Intervention: HbA1c ≥5.9% (41 mmol/mol)
Number of subjects: 16122

Group type: EXPERIMENTAL
Intervention: HbA1c 5.9-6.4% (41-46 mmol/mol)
Number of subjects: 16122
Study: 25191915

Group type: EXPERIMENTAL
Intervention: Low-dose buprenorphine (0.2-1.6 mg/d, mean dose 0.4 mg/d, mean maximum dose 0.7 mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-dose buprenorphine
Number of subjects: 15
Study: 25191939

Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-inh) administered intravenously at a dose 30-fold greater than that approved for hereditary angioedema (HAE).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-inh) at a dose of 2000 units in humans.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-inh) combined with polysulfated macromolecules (heparin and dextran sulfate).
Number of subjects: 0
Study: 25192373

Group type: EXPERIMENTAL
Intervention: AOSpine Knowledge Forum Tumor model for data collection
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Prospective data collection
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Retrospective data review
Number of subjects: 1495
Study: 25192414

Group type: EXPERIMENTAL
Intervention: Blinatumomab treatment
Number of subjects: 0
Study: 25192745

Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.
Number of subjects: 106
Study: 25193617

Group type: EXPERIMENTAL
Intervention: Delayed-release mesalamine tablets formulated with MMX technology, 8 weeks of treatment for active mild-to-moderate UC.
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Delayed-release mesalamine tablets formulated with MMX technology, 12 months of maintenance treatment for quiescent UC.
Number of subjects: 343
Study: 25193672

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 2227
Study: 25193933

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25195991

Group type: EXPERIMENTAL
Intervention: Screening using computed tomography angiography (CTA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CVD-specific counseling
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Screening (CTA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Baseline and post-screening questionnaires
Number of subjects: 48
Study: 25196123

Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant protein-1 (MCP-1)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Macrophage inflammatory protein-1α (MIP-1α)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Regulated upon activation normal T cell expressed and secreted (RANTES)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: RANTES
Number of subjects: 581
Study: 25196783

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 60
Study: 25197009

Group type: EXPERIMENTAL
Intervention: Deferasirox (once daily)
Number of subjects: 86
Study: 25198021

Group type: EXPERIMENTAL
Intervention: CRSwNP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CRSsNP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 25198193

Group type: COMPARATOR
Intervention: Icatibant administered by healthcare professionals (HCPs) in FAST-3
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Icatibant administered by healthcare professionals (HCPs) in IOS
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Icatibant (combined HCP and self-administration) in IOS
Number of subjects: 145
Study: 25198661

Group type: EXPERIMENTAL
Intervention: Endostar (15 mg/day) combined with gemcitabine (1,000 mg/m(2) on days 1 and 8) and cisplatin (80 mg/m(2) on day 1) for a maximum of four cycles.
Number of subjects: 30
Study: 25199919

Group type: EXPERIMENTAL
Intervention: Striatal dopamine D2-like receptor binding potential (D2BP) measured using positron emission tomography with [(18)F]fallypride
Number of subjects: 43
Study: 25199997

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg single dose
Number of subjects: 32
Study: 25200052

Group type: COMPARATOR
Intervention: HeartWare Ventricular Assist Device only
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Concurrent valve procedures
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: No tricuspid valve procedure (TVP)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Preimplant tricuspid regurgitation severity
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 382
Study: 25200593

Group type: EXPERIMENTAL
Intervention: Postoperative experience as described by patients and caregivers through daily diary entries assessing functional autonomy, postoperative pain, and caregiver burden.
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Daily diary responses from patients and caregivers regarding their postoperative experience.
Number of subjects: 105
Study: 25200610

Group type: EXPERIMENTAL
Intervention: (64)Cu-MM-302
Number of subjects: 0
Study: 25201017

Group type: EXPERIMENTAL
Intervention: Peak isometric muscle force measurements for lower extremity (LE) muscle groups
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Habitual walking
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fast walking
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Scaled LE peak muscle forces
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weaker subjects
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Peak isometric force of the knee flexors and ankle plantar flexors
Number of subjects: 42
Study: 25201125

Group type: EXPERIMENTAL
Intervention: DuraSeal polyethylene glycol (PEG) gel used as a spacer during low-dose rate brachytherapy.
Number of subjects: 0
Study: 25201318

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment for 8 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: COMT Met-carriers
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fractional anisotropy measure
Number of subjects: 58
Study: 25201624

Group type: EXPERIMENTAL
Intervention: Adult Myopathy Assessment Tool (AMAT)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: AMAT items
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: AMAT total scores
Number of subjects: 114
Study: 25202139

Group type: EXPERIMENTAL
Intervention: Once-weekly bortezomib 1.6 mg/m²
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Twice-weekly bortezomib 1.3 mg/m²
Number of subjects: 70
Study: 25203178

Group type: EXPERIMENTAL
Intervention: Methicillin-susceptible Staphylococcus aureus (MSSA) SSTI
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (MRSA) SSTI
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: MRSA SSTI
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: MSSA SSTI
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Overall S. aureus colonization
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Pulsed-field gel electrophoresis (PFGE) analysis
Number of subjects: 1203
Study: 25203869

Group type: EXPERIMENTAL
Intervention: Galactomannan test (cut-off 0.5)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Galactomannan test (cut-off 1.0)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Galactomannan test (cut-off 3.0)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: β-D-glucan test (cut-off 80 pg/ml)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: β-D-glucan test (cut-off 200 pg/ml)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Lateral-flow device tests
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Mycological culture
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Probable/proven invasive pulmonary aspergillosis
Number of subjects: 221
Study: 25204423

Group type: EXPERIMENTAL
Intervention: Patient educational materials (PEMs) from Women & Infants Hospital
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient educational materials (PEMs) from four laboratories in the US and one in Europe
Number of subjects: 0
Study: 25204541

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Baseline pain severity
Number of subjects: 159
Study: 25204854

Group type: EXPERIMENTAL
Intervention: Increased risk of obstructive sleep apnea (OSA) assessed by the Berlin Questionnaire.
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Increased risk of cardiometabolic disease (CMR) assessed by biomarkers including Lipid Accumulation Product (LAP) and Triglyceride-Glucose Index (TyG Index).
Number of subjects: 302
Study: 25204977

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Former intensive group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Former conventional treatment group
Number of subjects: 0
Study: 25205777

Group type: EXPERIMENTAL
Intervention: Psychosocial assessments (Mental Health Assessment and Dynamic Referral for Oncology)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Previous history of mental health counseling, total number of cancer-related symptoms, and race/ethnicity
Number of subjects: 836
Study: 25205858

Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis with monopolar return, anodic-first polarity, short pulse widths (100 μs), long interphase gaps (500 μs), and high stimulation rates (≥400 pps)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis
Number of subjects: 3
Study: 25207162

Group type: EXPERIMENTAL
Intervention: High-magnitude whole-body vibration
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-magnitude whole-body vibration
Number of subjects: 34
Study: 25207813

Group type: EXPERIMENTAL
Intervention: More recess physical activity (PA)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Higher levels of total PA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Physically active school transportation
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: More time spent in sedentary behavior (SB)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Total PA
Number of subjects: 186
Study: 25208108

Group type: EXPERIMENTAL
Intervention: Individualized treatment approaches for abdominal pain in IBD patients; specific interventions not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of the source(s) of pain in patients with IBD; specific interventions not detailed.
Number of subjects: 0
Study: 25208608

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 488
Study: 25209003

Group type: EXPERIMENTAL
Intervention: Multi-omic molecular profiling (MMP) informed selection of approved cancer treatments
Number of subjects: 28
Study: 25209376

Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin combined with bevacizumab (four cycles, final cycle without bevacizumab)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin combined with bevacizumab
Number of subjects: 46
Study: 25209396

Group type: EXPERIMENTAL
Intervention: Intravesical sphingomyelin liposomes (4 weekly instillations)
Number of subjects: 14
Study: 25209657

Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy (VCE)
Number of subjects: 200
Study: 25210104

Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) administered for 30 days, median dose 5.65 mg/kg/day twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) administered for 30 days
Number of subjects: 12
Study: 25210883

Group type: EXPERIMENTAL
Intervention: Standard 4-hour glucagon stimulation test (GST) with a peak GH cutoff of 3 ng/mL
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Standard 4-hour glucagon stimulation test (GST) with a peak GH cutoff of 1 ng/mL
Number of subjects: 108

Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 108
Study: 25211055

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 15990

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 15990
Study: 25211344

Group type: EXPERIMENTAL
Intervention: DNA/Ad
Number of subjects: 15

Group type: COMPARATOR
Intervention: AdCA
Number of subjects: 15
Study: 25211526

Group type: EXPERIMENTAL
Intervention: Endosonography alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Endosonography with mediastinoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endosonography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 100
Study: 25212533

Group type: EXPERIMENTAL
Intervention: NAVAal (3.1 ± 1.1 cmH2O/μV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NAVAhigh
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NAVAlow
Number of subjects: 10

Group type: COMPARATOR
Intervention: PSVal (17 ± 2 cmH20)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PSVhigh
Number of subjects: 10

Group type: COMPARATOR
Intervention: PSVlow
Number of subjects: 10
Study: 25213088

Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 31
Study: 25213183

Group type: EXPERIMENTAL
Intervention: Vorinostat maintenance therapy (oral agent) for 21 consecutive days starting day + 60 after autologous transplant, followed by a week off for up to 11 cycles.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Vorinostat maintenance therapy
Number of subjects: 23
Study: 25213604

Group type: EXPERIMENTAL
Intervention: Specific exercise strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control exercise group
Number of subjects: 0
Study: 25213741

Group type: EXPERIMENTAL
Intervention: Women veterans
Number of subjects: 24965

Group type: EXPERIMENTAL
Intervention: African-American female veterans
Number of subjects: 24965

Group type: EXPERIMENTAL
Intervention: African-American veterans with diabetes
Number of subjects: 24965
Study: 25214022

Group type: EXPERIMENTAL
Intervention: Pregnancy with live birth deliveries
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pregnancy with transient worsening of renal function
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Uncomplicated pregnancy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Uncomplicated pregnancy after previous pregnancy
Number of subjects: 12
Study: 25214517

Group type: EXPERIMENTAL
Intervention: W28 arm (24 weeks of BOC/PEGIFN/RBV after 4 weeks of PEGIFN/RBV lead-in)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: W48 arm (44 weeks of BOC/PEGIFN/RBV after 4 weeks of PEGIFN/RBV lead-in)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall SVR12TND rate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 21
Study: 25214544

Group type: EXPERIMENTAL
Intervention: Early-stage CRC patients
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Women with early-stage CRC
Number of subjects: 291
Study: 25214838

Group type: EXPERIMENTAL
Intervention: Carriage of the A allele of the FTO rs9939609 gene
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: Poor metabolic control
Number of subjects: 1119
Study: 25216871

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 68
Study: 25217112

Group type: EXPERIMENTAL
Intervention: BIL >1 mg/dl (>17.1 µmol/l) and CHE ≤ 5,900 U/l
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: 90-days mortality
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: MELD, APRI, and CPT scores
Number of subjects: 336
Study: 25217217

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study: 25217392

Group type: EXPERIMENTAL
Intervention: Dinaciclib + Rituximab
Number of subjects: 5
Study: 25217734

Group type: EXPERIMENTAL
Intervention: Low 25(OH)D levels (Group 1a, ≤5 ng/mL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Low 25(OH)D levels (Group 1b, 5-15 ng/mL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Normal 25(OH)D levels (Group 2, >15 ng/mL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Comparison between Group 1a and Group 1b
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Higher 25(OH)D levels
Number of subjects: 81
Study: 25218256

Group type: EXPERIMENTAL
Intervention: Real iTBS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 72
Study: 25218544

Group type: EXPERIMENTAL
Intervention: Rapid deployment aortic valve replacement using a stented trileaflet bovine pericardial bioprosthesis
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Rapid deployment aortic valve replacement
Number of subjects: 287